Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells $8,739,177.75 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) CEO August Troendle sold 13,995 shares of the company’s stock in a transaction on Friday, August 21st. The stock was sold at an average price of $624.45, for a total value of $8,739,177.75. Following the sale, the chief executive officer owned 547,200 shares of the company’s stock, valued at $341,699,040. This trade represents a 2.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Medpace Stock Down 1.1%

NASDAQ MEDP traded down $6.66 on Tuesday, reaching $613.37. The company had a trading volume of 246,088 shares, compared to its average volume of 346,263. The company’s fifty day moving average is $553.21 and its 200 day moving average is $492.40. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $677.90. The stock has a market capitalization of $17.12 billion, a P/E ratio of 35.95, a P/E/G ratio of 2.77 and a beta of 1.15.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The firm had revenue of $707.33 million for the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The business’s revenue for the quarter was up 17.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, research analysts expect that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Institutional Trading of Medpace

Hedge funds have recently added to or reduced their stakes in the stock. Johnson Financial Group Inc. purchased a new stake in shares of Medpace during the 2nd quarter worth approximately $27,000. Geneos Wealth Management Inc. lifted its stake in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after purchasing an additional 37 shares during the last quarter. Elyxium Wealth LLC purchased a new position in Medpace in the fourth quarter valued at approximately $30,000. Jones Financial Companies Lllp bought a new position in Medpace during the second quarter valued at $30,000. Finally, Allied Private Wealth LLC bought a new position in Medpace during the second quarter valued at $31,000. Institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

MEDP has been the subject of a number of recent analyst reports. Robert W. Baird upped their price objective on shares of Medpace from $547.00 to $624.00 and gave the stock a “neutral” rating in a research report on Friday, July 24th. Weiss Ratings upgraded Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and upped their target price for the company from $490.00 to $515.00 in a report on Tuesday, July 7th. Royal Bank Of Canada increased their price target on Medpace from $484.00 to $692.00 and gave the company an “outperform” rating in a research report on Friday, July 24th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.